medigraphic.com
ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)

2021, Number 3

<< Back Next >>

Rev Cubana Hematol Inmunol Hemoter 2021; 37 (3)

Therapeutic news in chronic lymphoid leukemia

Concepción FY, Quintero SY, Romero GA

Language: Spanish
References: 33
Page: 1-13
PDF size: 277.60 Kb.


ABSTRACT

Introduction: Chronic lymphoid leukemia is a chronic lymphoproliferative neoplasm characterized by the increase of a dysfunctional lymphoid clonal population with immunophenotype B (> 95%) and exceptionally T (<5%), it mainly affects people over 55 years of age, increasing towards the seventh decade of life.
Objective: To analyze the main therapeutic modalities for the management of chronic lymphoid leukemia.
Methods: A literature review was carried out, in English and Spanish, through the PubMed website and the academic search engine Google for articles published in the last 5 years. An analysis and summary of the revised bibliography was made.
Analysis and synthesis of the information: Chronic lymphoid leukemia was considered for decades a disease of the elderly patient, generally of an indolent course, unpredictable and incurable evolution. The treatment of this disease has undergone in the last 30 years very significant changes that have had a favorable impact on the increase in the overall and disease-free survival of patients who suffer from it.
Conclusion: Adequate follow-up of patients with chronic lymphoid leukemia must be maintained, as this will make it possible to reduce complications, progression and increase overall survival as much as possible.


REFERENCES

  1. Hallek M, Cheson BD, Catovsky D, Caligaris-Capio F, Dighiero G, Dohner H et al. IWCLL guidelines for diagnosis, indications for treatment, response assessment and suppportive management of CLL. Blood. 2018 Jun;131(25): 2745-60.

  2. Quintero Sierra Y. En: Enfermedades del sistema linfoide. Colectivo de autores. Enfermedades hematológicas. Diagnóstico y tratamiento. La Habana: Ciencias Médicas, 2018. ISBN 978-959-313-646-4, ISBN 978-959-313-647-1 (PDF), ISBN 978-959-313-648-8 (Epub)

  3. Martín GP, Puerta JM, Chacón MJ. Leucemia linfática crónica B. Diagnóstico, pronóstico y tratamiento. Actual Med 2017; 100:(800):52-3. DOI: https://10.15568/am.2017.800.ao01

  4. Valdespino-Gómez VM. Leucemia linfocítica crónica de linfocitos B: un modelo personalizado de valoración clínica y molecular. Rev Hematol Mex. 2014; 15:103-21.

  5. Pflug N, Bahlo J, Shanafelt TD, Eichhorst BF, Bergmann MA, Elter T, et al.: Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. Blood. 2014;124 (1): 49-62.

  6. Bain BJ, Bates I, Laffan MA. Dacie and Lewis. Hematología Práctica. 12a Ed. España: Elsevier; 2018.

  7. Cuker A, Altman JK, Gerds AT, Wun T. American Society of Hematology Self-Assessment Program. 7ma Ed. Whashington; 2019.700-18.

  8. Lazarian G, Guièze R, Wu CJ. Clinical implications of novel genomic discoveries in chronic lymphocytic leukemia. J Clin Oncol. 2017;35(9):984-93.

  9. Hoffman R, Benz EJ, Silberstein LE, Heslop HE, Weitz JI, Anastasi J. Hematology Basic principles and practice. 7th Ed. Florida: Elsevier Health;2019.

  10. Strati P, Shanafelt TD: Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification. Blood.2015;126(4):454-62.

  11. Hallek M, Shanafelt TD, Eichhorst B. Chronic lymphocytic leukaemia. Lancet. 2018;391 (10129): 1524-1537.

  12. Developments in the treatment of lymphoproliferative disorders: rising to the new challenges of CLL therapy. A report of a symposium presented during the 48th American Society of Hematology Annual Meeting and Exposition, December 8, 2006, Orlando, Florida. Clin Adv Hematol Oncol. 2007;5 (3 Suppl 5): 1-14; quiz 15-6.

  13. Kai KR, Stilgenbauer S. Staging and prognosis if chronic lymphocytic leukemia(Internet). Up to Date. 2016 (cited 2017 Mar 27). Disponible en: https://www.uptodte.com/contents/staging-and-prognosis-of-chronic-lymphocytic-leukemia.

  14. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood.2016;127(20):2391-405.

  15. Molica S, Giannarelli D, Mirabelli R, Levato L, Levato D, Lentini M et al. Chronic lymphocytic leukemia international prognostic index (CLL-IPI) in patients receiving chemoimmuno or targeted therapy: a systematic review and meta-analysis. Ann Hematol. 2018 Oct; 97(10):2005-8.

  16. Farooqui MZ, Valdez J, Martyr S, AUE G, Saba N, Niemann CU et al. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. Lancet Oncol. 2015;16(2):169-76.

  17. Stilgenbauer S, Eichhorst B, Schetelig J, Coutre S, Seymour JF, Munir T, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncology 2016; 17(6):768-78.

  18. Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF et al. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med 2016;374 (4):311-22.

  19. O'Brien S, Furman RR, Coutre SE, Sharman JP, Burger JA, Blum KA, et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: An open-label, multicentre, phase 1b/2 trial. Lancet Oncol. 2014; 15(1):48-58.

  20. Shanafelt T, Wang V, Kay NE, Hanson CA, O'Brien SM, Barrientos JC et al. LBA-4 A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy Vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL): A Trial of the ECOG-ACRIN Cancer Research Group (E1912). 2018 ASH Annual Meeting Abstracts. Blood.2018. Abstract LBA-4.

  21. Eichhorst B, Fink AM, Bahlo J, Busch R, Kovacs G, Maurer C, et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2016;17(7):928-42.

  22. Barr P, Robak T, Owen CJ, Tedeschi A, Bairey O, Bartlett NL et al. Updated efficacy and safety from the phase 3 RESONATE-2 study: ibrutinib as first-line treatment option in patients 65 years and older with chronic lymphocytic leukemia/small lymphocytic leukemia. Blood.2016;128:234.

  23. Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W et al. Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. N Engl J Med. 2018; 379(26):2517-28.

  24. Goede V, Fischer K, Engelke A, Schlag R, Lepretre S, Montero LFC et al. Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study. Leukemia. 2015;29(7):1602-4.

  25. Moreno C, Greil R, Demirkan F, Tedeschi A, Anz B, Larratt L et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019; 20(1):43-56.

  26. Fischer K, Bahlo J, Fink AM, Goede V, Herling CD, Cramer P, et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood.l2016; 127(2):208-16.

  27. Chai-Adisaksopha C, Brown JR. FCR achieves long-term durable remissions in patients with IGHV mutated CLL. Blood. 2017;130(21):2278-82.

  28. Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med.2014;371(3):213-23.

  29. Munir T, Brown J, O´Brien S, Barrientos JC, Barr PM, Reddy NM et al. Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol.2019; 94:1353-63.

  30. Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D'Rozario J, Assouline S et al. Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. NEJM. 2018;378:1107-1120

  31. Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 2014;370(11):997-1007.

  32. Mato A.R., Roeker L.E., Jacobs R., Hill B.T., Lamanna N., Brander D., Shadman M., Ujjani C.S., Yazdy M.S., Perini G.F., et al. Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy. Clin Cancer Res. 2020 Jul 15;26(14):3589-3596. DOI: https://10.1158/1078-0432.CCR-19-3815

  33. O Brien S, Byrd JC, Hillmen P, Coutre S, Brown JR, Barr PM et al. Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia. Am J Hematol 2019;May 94(5): 554-62.




2020     |     www.medigraphic.com